

Identifying and Managing Patients at Risk for Life-Threatening Allergic Reactions

Anaphylaxis is a severe, life-threatening systemic allergic reaction that poses serious consequences for at-risk patients.¹ This program, sponsored by Mylan Specialty, will utilize an interactive case-based approach to discuss the value of initiating a dialogue with patients and their caregivers about life-threatening allergic reactions and best practices for identifying patients at risk. Evidence-based management and preparedness strategies will also be highlighted, including vigilant allergen avoidance and the role of the epinephrine auto-injector as first-line treatment.^{2,3} Key attributes and educational resources associated with EpiPen 2-Pak® (epinephrine) Auto-Injectors for the management of life-threatening allergic reactions will be discussed in the context of this approach.

Host
Cori Cross, MD, FAAP
Member-At-Large
AAP-CA Chapter 2

Wednesday, December 2, 2015 6:30 PM
Dinner
and Presentation

Valentino's
 3115 Pico Boulevard
 Santa Monica, CA 90405
 (310) 829-4313

Faculty Presenter
Jacob Offenberger, MD

Indications

EpiPen® (epinephrine) 0.3 mg and EpiPen Jr® (epinephrine) 0.15 mg Auto-Injectors are indicated in the emergency treatment of type 1 allergic reactions, including anaphylaxis, to allergens, idiopathic and exercise-induced anaphylaxis, and in patients with a history or increased risk of anaphylactic reactions. Selection of the appropriate dosage strength is determined according to body weight.

Important Safety Information

EpiPen Auto-Injectors should only be injected into the anterolateral aspect of the thigh. **DO NOT INJECT INTO BUTTOCK, OR INTRAVENOUSLY.** Epinephrine should be used with caution in patients with certain heart diseases, and in patients who are on drugs that may sensitize the heart to arrhythmias, because it may precipitate or aggravate angina pectoris and produce ventricular arrhythmias.

Arrhythmias, including fatal ventricular fibrillation, have been reported in patients with underlying cardiac disease or taking cardiac glycosides or diuretics. Patients with certain medical conditions or who take certain medications for allergies, depression, thyroid disorders, diabetes, and hypertension, may be at greater risk for adverse reactions. Other adverse reactions include transient moderate anxiety, apprehensiveness, restlessness, tremor, weakness, dizziness, sweating, palpitations, pallor, nausea and vomiting, headache, and/or respiratory difficulties.

EpiPen and EpiPen Jr Auto-Injectors are intended for immediate self-administration as emergency supportive therapy only and are not intended as a substitute for immediate medical or hospital care.

Please see additional Important Safety Information and accompanying full Prescribing Information.

REGISTER TODAY TO ATTEND THIS PROGRAM.

Space is limited and will be granted on a first-come/first-served basis. For additional information, please speak with your local Mylan Specialty L.P. representative.

Please note ME # or State License # is required for program registration and entry to a program.

2 WAYS TO REGISTER:

1. Call Steffi Ewing at (404) 441-5549.
2. Send an email to steffi.ewing@mylan.com

Please include your full name and telephone number so that we may call you to complete your registration.

This is not a continuing medical education program and credits will not be given for attendance. A plated meal will be provided in conjunction with this program, which requires that Mylan Specialty track which health care professionals receive these meals for federal and, in some cases, state reporting purposes. At sign-in on the day of the program, you may elect to not participate in the meal.

References: 1. Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. *J Allergy Clin Immunol.* 2006;117(2):391-397. 2. Simons FER, Arduso LRF, Bilo MB, et al; for the World Allergy Organization. World Allergy Organization guidelines for the assessment and management of anaphylaxis. *World Allergy Organ J.* 2011;4(2):13-37. 3. Boyce JA, Assa'ad A, Burks AW, et al; NIAID-Sponsored Expert Panel. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-Sponsored Expert Panel. *J Allergy Clin Immunol.* 2010;126(6 suppl):S1-S58.



Mylan® and the Mylan logo are registered trademarks of Mylan Specialty L.P.
 EpiPen®, EpiPen Jr®, EpiPen 2-Pak®, and EpiPen Jr 2-Pak®
 are registered trademarks of Mylan Specialty L.P.

